Published in JAMA on October 13, 2004
The Clinical Effectiveness of Pneumococcal Conjugate Vaccines. Dtsch Arztebl Int (2016) 1.49
A randomized placebo-controlled trial of acetaminophen for prevention of post-vaccination fever in infants. PLoS One (2011) 1.00
Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol (2011) 0.88
Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull World Health Organ (2008) 0.87
Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits. Can J Infect Dis Med Microbiol (2006) 0.82
Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites. Dermatol Ther (Heidelb) (2016) 0.75
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA (2009) 5.58
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 3.63
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA (2006) 3.41
Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol (2004) 2.79
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis (2004) 2.68
Autologous cultured chondrocytes: adverse events reported to the United States Food and Drug Administration. J Bone Joint Surg Am (2006) 2.50
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum (2002) 2.12
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int (2007) 2.03
Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf (2005) 2.00
Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics (2002) 1.98
Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol (2004) 1.89
Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA (2005) 1.84
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol (2005) 1.82
A novel technique of retrograde nasal intubation for the Pierre Robin Sequence infant with a known difficult airway. Paediatr Anaesth (2009) 1.80
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J (2004) 1.76
The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf (2012) 1.73
Efficacy of radiofrequency ablation for twin-reversed arterial perfusion sequence. Am J Obstet Gynecol (2007) 1.70
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. MMWR Surveill Summ (2003) 1.70
Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion (2012) 1.66
Adverse event reports following yellow fever vaccination. Vaccine (2008) 1.63
Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics (2008) 1.63
Guillain-Barré syndrome following influenza vaccination. JAMA (2004) 1.59
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum (2003) 1.58
Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med (2003) 1.51
Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Vaccine (2008) 1.48
Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol (2013) 1.46
Anesthesia for in utero repair of myelomeningocele. Anesthesiology (2013) 1.45
Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine (2009) 1.40
Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transpl Int (2010) 1.39
Flaws undermine results of UK biotech debate. Nature (2003) 1.39
On the hazard ratios and corresponding confidence intervals that appear in Basran et al. (2006). Anesth Analg (2007) 1.39
Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection. J Am Med Inform Assoc (2011) 1.36
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation (2008) 1.34
Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol (2012) 1.28
Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. Nephrology (Carlton) (2012) 1.20
Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Drug Discov Today (2010) 1.18
A comprehensive approach to percutaneous injury prevention during phlebotomy: results of a multicenter study, 1993-1995. Infect Control Hosp Epidemiol (2003) 1.16
Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf (2005) 1.10
Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety. Pediatrics (2011) 1.09
Expression and functional characterization of the RIG-I-like receptors MDA5 and LGP2 in Rainbow trout (Oncorhynchus mykiss). J Virol (2011) 1.06
Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem (2012) 1.05
Developing tailored immunization materials for concerned mothers. Health Educ Res (2007) 1.05
CDC grand rounds: Reducing the burden of HPV-associated cancer and disease. MMWR Morb Mortal Wkly Rep (2014) 1.05
CDC Grand Rounds: global tobacco control. MMWR Morb Mortal Wkly Rep (2014) 1.04
Orphan products: an emerging trend in drug approvals. Nat Rev Drug Discov (2010) 1.04
Vaccine adverse event text mining system for extracting features from vaccine safety reports. J Am Med Inform Assoc (2012) 1.01
Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. Clin Infect Dis (2008) 0.99
Glioma surgical aspirate: a viable source of tumor tissue for experimental research. Cancers (Basel) (2013) 0.99
Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data. Stat Med (2005) 0.98
Assays to detect West Nile virus in dead birds. Emerg Infect Dis (2005) 0.98
Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA (2005) 0.96
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant (2004) 0.96
Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet (2002) 0.96
Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci (2009) 0.96
Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine (2006) 0.95
Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med (2002) 0.95
Functional characterization of a nonmammalian IL-21: rainbow trout Oncorhynchus mykiss IL-21 upregulates the expression of the Th cell signature cytokines IFN-gamma, IL-10, and IL-22. J Immunol (2010) 0.94
Therapies for inborn errors of metabolism: what has the orphan drug act delivered? Pediatrics (2010) 0.94
Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine (2007) 0.94
Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans. Pharmacoepidemiol Drug Saf (2008) 0.93
Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program. Pediatrics (2011) 0.93
Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health (2012) 0.93
The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf (2012) 0.92
Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response. J Virol (2007) 0.92
Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics (2005) 0.91
Application of information retrieval approaches to case classification in the vaccine adverse event reporting system. Drug Saf (2013) 0.91
Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine (2005) 0.90
Zidovudine and perinatal human immunodeficiency virus type 1 transmission: a population-based approach. Pediatrics (2002) 0.90
Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr Infect Dis J (2009) 0.90
Differential maternal responses to a newly developed vaccine information pamphlet. Vaccine (2009) 0.90
Parental concerns and medical-seeking behavior after immunization. Am J Prev Med (2006) 0.90
Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). Drug Saf (2008) 0.90
A global regulatory science agenda for vaccines. Vaccine (2013) 0.89
Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf (2007) 0.89
What should an ideal vaccine postlicensure safety system be? Am J Public Health (2009) 0.89
Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol (2003) 0.88
The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine (2007) 0.88
An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone? Pediatrics (2004) 0.88
Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol (2006) 0.87